GNCA

Genocea Biosciences Stock Price

2.30
-0.02 (-0.86%)
Upgrade to Real-Time
Afterhours (Closed)
2.30
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Genocea Biosciences Inc GNCA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -0.86% 2.30 20:00:00
Close Price Low Price High Price Open Price Previous Close
2.30 2.2552 2.33 2.33 2.32
Bid Price Ask Price Spread News
2.18 2.35 0.17 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
477 87,314 $ 2.28 $ 199,435 432,334 1.10 - 6.83
Last Trade Time Type Quantity Stock Price Currency
16:00:00 775 $ 2.30 USD

Genocea Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 118.12M 51.36M 40.70M $ - $ - -2.19 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 31.51M 0.60%

more financials information »

Genocea Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GNCA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.682.752.25522.46289,873-0.38-14.18%
1 Month2.122.752.092.41262,6970.188.49%
3 Months3.423.581.952.64585,163-1.12-32.75%
6 Months2.006.831.743.22756,3370.3015.0%
1 Year2.616.831.102.99486,254-0.31-11.88%
3 Years1.4912.220.282.11548,4670.8154.36%
5 Years4.4212.220.283.11539,540-2.12-47.96%

Genocea Biosciences Description

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.


Your Recent History
NASDAQ
GNCA
Genocea Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.